| II. TERMINATED AGREEMENTS | |||
|
Auxilium Pharmaceuticals Inc. (AUXL) |
Oscient Pharmaceuticals Corp. (OSCI) | The companies terminated a deal for the co-promotion of Testim 1%, a topical testosterone replacement gel | Auxilium plans to increase its sales force coverage; it will pay Oscient a $1.8M early termination fee (9/5) |
|
Cubist Pharmaceuticals Inc. (CBST) |
XOMA Ltd. (XOMA) | XOMA placed production process development work for Cubist on hold, and issued a notice of contract termination | The move, related to Cubist's HepeX-B product for hepatitis B, came after Cubist said it was ending its investment in the program (7/28) |
|
Curis Inc. (CRIS) |
Genentech Inc. (NYSE:DNA) | Curis opted out of 2003 deal to co-develop a basal cell carcinoma drug candidate | They previously had stopped enrollment in a Phase I trial; other collaborations between the companies were not affected (9/1) |
| | |||
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| NYSE = New York Stock Exchange. | |||
To read more on related topics, click on one of the words below.